Eisai Showcases Oncology Portfolio And Pipeline At ASCO 2024
(MENAFN- PR Newswire) Biomarker Analyses from Pivotal Phase 3 CLEAR Trial in Patients with Advanced Renal Cell Carcinoma Will Be Featured in an Oral Presentation Additional Data From Eisai's Pipeline Provide Insights Into Metastatic Breast Cancer and …